Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

PKinUK16 Aug. 25 at 2:49 AM

$ESPR great point. $300 million worth of EU DSE milestones not priced into this stock. The royalty stream was given up but not the milestones. My guess is that the first milestone is worth $75-$100 million and that would be hit in the next 9-12 months from now.

1 · Reply

Deliver1 Aug. 25 at 2:22 AM

$ESPR Just my opinion: I beleive the sale ( by Esperion)of the worlwide rights to BA is a strong possibility. Potential Buyer: DS / Otsuka Seller: Esperion Appraisal for BA ( Nexletol) completed = legal protocol https://www.giiresearch.com/report/tbrc1769674-nexletol-global-market-report.html Litigation on remaining generic challengers needs to be settled first. Could this be what's brewing on Omar's charts? - time will tell, imo.

0 · Reply

nomalarkey Aug. 24 at 11:46 PM

$ESPR The new spokesman for BA in the EU that will be rolled out this coming week will be:

0 · Reply

djohnson591 Aug. 24 at 11:41 PM

$ESPR Remember, it looks like there will be new guidelines released at this years ESC Congress. This could be a huge boost to DSE sales and help revert those milestones back to ESPR at a quicker pace.

0 · Reply

djohnson591 Aug. 24 at 11:40 PM

$ESPR These are some of the sessions that will feature BA at the ESC Congress this week! - Shaping the dyslipidaemia treatment algorithm: real-world insights and the expanding role of bempedoic acid in oral triple therapy. Sponsored by Daiichi Sankyo - Advancing lipid management: insights from real-world evidence and combination therapy trials. Sponsored by Daiichi Sankyo - Bempedoic acid in clinical practice. - Bempedoic acid does not affect skeletal muscle mitochondrial activity in hypercholesterolemic mice - New treatments for dyslipidemia in older patients? Real-life analysis of the use of bempedoic acid in the elderly population. Continued.....

1 · Reply

Gary9912 Aug. 24 at 11:30 PM

$ESPR 👀👀👀 https://esc365.escardio.org/ESC-Congress/programme?text=Bempedoic&docType=All&days&page=1&vue=cards

0 · Reply

omar_progressivetrading Aug. 24 at 10:07 PM

$ESPR | The Power of the Uptrend The uptrend is in motion. It started on the hourly, moved into the daily, and now the weekly chart looks ready to join the party in the coming weeks. That’s when you just sit back, relax, and let your strategy do the work. One thing you need to know about $ESPR: once it locks into a trend, the ride is no joke. Look back at late 2014 and early 2017, those waves were unforgettable. Yes, the trading action will get wild, and many will tap out. But based on the data, everything points to strength for the years ahead and the charts are confirming it. So the real question is: Are you here for the short term or the long term? Either way… we’ll both be landing on the moon, with or without you. To The Moon & Beyond! 🫡 🌖

1 · Reply

Albertowest Aug. 24 at 9:49 PM

$ESPR oops, talking to yourself means two things, either you are totally insane or you mistakenly used same account to generate a fake conversation. Anyway James/Kurt/Bubba/MO Money/etc CAN’T STOP WHATS COMING

3 · Reply

Gary9912 Aug. 24 at 9:31 PM

$ESPR Another good study showcasing the importance of hscrp in cardiovascular outcomes. Yes BA lowers hscrp levels and guess what class of injection/expensive drugs don’t do that, yep you guessed it, PCSK9s don’t!!! IMHO - You simply can’t have enough shares here while this remains under $5Z https://pubmed.ncbi.nlm.nih.gov/40472800/

1 · Reply

OldManLogan Aug. 24 at 8:38 PM

$ESPR Anyone planning on selling when we get back to $4 shortly should look loooong and hard at that chart, before doing that.

2 · Reply

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 5, 2025, 10:10 AM EDT - 19 days ago

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:00 AM EDT - 19 days ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 4 weeks ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 7 weeks ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 14, 2025, 7:03 AM EDT - 2 months ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

May 12, 2025, 8:00 AM EDT - 3 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 3 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 6:30 AM EDT - 3 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 10:49 AM EDT - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 8:00 AM EDT - 4 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 4 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 4 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 1, 2025, 8:00 AM EDT - 5 months ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 10:34 AM EST - 6 months ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 6:00 AM EST - 6 months ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 6 months ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 6 months ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Dec 18, 2024, 7:00 AM EST - 8 months ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 9 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 9 months ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 9 months ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 9 months ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Nov 18, 2024, 10:30 AM EST - 9 months ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 13, 2024, 2:08 AM EST - 10 months ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 7, 2024, 1:35 PM EST - 10 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:00 AM EST - 10 months ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 10 months ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 10 months ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 11 months ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:10 AM EDT - 1 year ago

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Aug 16, 2024, 4:09 AM EDT - 1 year ago

Esperion Therapeutics: Strategically Positioned To Grow

Aug 12, 2024, 9:50 PM EDT - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jul 16, 2024, 8:00 AM EDT - 1 year ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

May 23, 2024, 9:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming June Investor Conferences

May 20, 2024, 6:00 AM EDT - 1 year ago

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

May 20, 2024, 5:43 AM EDT - 1 year ago

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 14, 2024, 8:00 AM EDT - 1 year ago

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

May 7, 2024, 10:05 AM EDT - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript

May 7, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports First Quarter 2024 Financial Results

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming May Investor Conferences

Apr 7, 2024, 2:45 PM EDT - 1 year ago

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Apr 1, 2024, 12:48 PM EDT - 1 year ago

Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Mar 25, 2024, 4:00 PM EDT - 1 year ago

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

PKinUK16 Aug. 25 at 2:49 AM

1 · Reply

Deliver1 Aug. 25 at 2:22 AM

0 · Reply

nomalarkey Aug. 24 at 11:46 PM

$ESPR The new spokesman for BA in the EU that will be rolled out this coming week will be:

0 · Reply

djohnson591 Aug. 24 at 11:41 PM

0 · Reply

djohnson591 Aug. 24 at 11:40 PM

1 · Reply

Gary9912 Aug. 24 at 11:30 PM

$ESPR 👀👀👀 https://esc365.escardio.org/ESC-Congress/programme?text=Bempedoic&docType=All&days&page=1&vue=cards

0 · Reply

omar_progressivetrading Aug. 24 at 10:07 PM

1 · Reply

Albertowest Aug. 24 at 9:49 PM

3 · Reply

Gary9912 Aug. 24 at 9:31 PM

1 · Reply

OldManLogan Aug. 24 at 8:38 PM

$ESPR Anyone planning on selling when we get back to $4 shortly should look loooong and hard at that chart, before doing that.

2 · Reply

Gary9912 Aug. 24 at 7:55 PM

$ESPR Cmon Esperion, let’s get Foody and @Gregg617 paid already, time is running out for both of them. Foody’s options are getting ready to expire and Gregg’s on his last, last chance agreement on the home front. Make it happen already. I know where Gregg lives, sleeping under a bridge this winter is not a good option for him.🥶 .

2 · Reply

Lskynrd1 Aug. 24 at 5:41 PM

$ESPR I wonder if we get any positive price movement this week or we will have to wait for the approval in a couple of weeks. We know its a winner so i hope we see some positive price action this week 👏🏆🚀💰

1 · Reply

BBRC Aug. 24 at 4:32 PM

$ESPR This stock has had two monster runs off of lows. The current setup is looking "fine." The company is significantly stronger than on the last two runs. The catalysts are stacking up. Japan is knocking on the door. Railbirds watching from the sidelines. Players have their cash on the table. It should be a good show.

1 · Reply

PKinUK16 Aug. 24 at 3:24 PM

$ESPR for Japanese Committee Meeting. If y’all see or know anything different than this feel free to add

0 · Reply

djohnson591 Aug. 24 at 2:04 PM

$ESPR Otsuka is gearing up for the launch with around 600 personnel, they're a top 3 Japanese BP. The Japanese also hate statins, so it's not whether or not it's going to be approved, it's all about the pricing tier.

4 · Reply

Fish2day Aug. 24 at 1:30 PM

$ESPR so this is the week, now the news could come before 29th, also their market are open before ours on Friday and we should hear before open on our market. Only think I’m concerned about is, what happens to our price if it doesn’t get approved, what price would we drop to? I sincerely hope not as the way I feel it’s pretty much a done deal, but you never know.

4 · Reply

Michael32180 Aug. 24 at 1:09 PM

$ESPR anyone remember Steve Martin's early stand up comedy routines? He talks about going to France..."it's like those French have a different word for e v e r y t h i n g...." I wonder a little about what might get lost in translation here...there seems to be enough interest outside of ST to keep the momentum even if there is no immediate PR after the Thursday meeting...but as DJ said, they are cutting it close with the time frame for the milestone payment. Once that payment comes through, even if it is only half, we should maintain or bounce up in price heading into next earnings. But like DJ mentioned, the last thing we need is dilution for what amounts to be a two week bridge loan,

0 · Reply

BioBum Aug. 24 at 12:34 PM

$ESPR think we get the ole dippimus rippimus in the coming weeks. There’s a key event that needs to happen in crunch time. Which means EASY shares to snag from retail by spooking them. Just like they did to me. Hang on tight. Maybe we see 1.80 again while we all question if we get Otsuka payment in time Similar to the RS talk when this fell to $1. My guess is we see at least 1.90s before next leg up. But I’m also bias in wanting more shares 😈. Load if it does!

1 · Reply

monster6969 Aug. 24 at 11:39 AM

$ESPR With a price above $5 we land Stocktwits Top 25 Russel 2000. That would be additional rocket fuel. What are you waiting for? From Monday, ..Let's go

1 · Reply

Enjoyycall Aug. 24 at 2:17 AM

$ESPR “Would you look at that”, all that raw inventory that posters said was going to be a waste or was mismanaged, hummm…or maybe BO requested. Onward and upward.

0 · Reply

Sanibelspeaks Aug. 24 at 12:34 AM

$ESPR so everyone who owns any biotech always says it’s a buyout candidate, but I think this one potentially could be bought out because of the uniqueness of the drug, thoughts

3 · Reply

BioBum Aug. 23 at 11:14 PM

$ESPR halted

2 · Reply

Market Cap	437.52M
Revenue (ttm)	332.31M
Net Income (ttm)	-51.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15.57%
Debt to Equity Ratio	-0.34

Volume	4,941,700
Avg Vol	4,583,948
Day's Range	N/A - N/A
Shares Out	201.62M
Stochastic %K	93%
Beta	0.82
Analysts	Sell
Price Target	$5.80